Flywheel, a Minneapolis-based medical imaging data and AI platform raises $54M in Series D funding, backed by tech giants including NVIDIA, Microsoft, and more.
Flywheel helps organizations turn complex imaging data into analysis-ready datasets for accelerated research and AI development. Flywheel offers comprehensive solutions for pharma companies, providers, payers, system integrators, AI developers and academic medical centers to get optimum value out of their data assets.
The funding will fuel Flywheel’s continued growth in its two primary markets (public sector healthcare and pharmaceutical companies) while accelerating expansion in other markets, including providers, payers, system integrators, and software companies seeking to harness the value of their data for AI development. The funding will also help Flywheel extend its global reach into key geographies, particularly across Europe.
Hereditary angioedema is characterised by regular, unpredictable attacks that lead to tissue swelling. The face is commonly affected. Image credit: Shutterstock/Velimir Zeland. The US Food
Seagen has deprioritized work on ladiratuzumab vedotin, the biotech quietly disclosed in its second quarter financial report Wednesday. Seagen has been studying the drug in
In this interview, Rob Trainor, the Vice President of Operations at Sphere Fluidics, sits down for an insightful conversation detailing the completion of Sphere Fluidics’ new
Flywheel Secures $54M for Medical AI Imaging Platform
by Jasmine Pennic Leave a Comment
What You Should Know:
FDA grants fast track status for Astria Therapeutics’ STAR-0215 – Pharmaceutical Technology
Hereditary angioedema is characterised by regular, unpredictable attacks that lead to tissue swelling. The face is commonly affected. Image credit: Shutterstock/Velimir Zeland. The US Food
Updated: Seagen deprioritizes antibody-drug candidate from $4.2B Merck deal
Seagen has deprioritized work on ladiratuzumab vedotin, the biotech quietly disclosed in its second quarter financial report Wednesday. Seagen has been studying the drug in
Sphere Fluidics’ Expansion and Vision
In this interview, Rob Trainor, the Vice President of Operations at Sphere Fluidics, sits down for an insightful conversation detailing the completion of Sphere Fluidics’ new